Browse Category

Food Industry News 14 October 2025 - 23 November 2025

Beyond Meat (BYND) Stock Today: Fresh Fraud Inquiry, Reverse Split Approval and a Deepening Meme-Stock Hangover

Beyond Meat (BYND) Stock Today: Fresh Fraud Inquiry, Reverse Split Approval and a Deepening Meme-Stock Hangover

On Sunday, November 23, 2025, Beyond Meat, Inc. (NASDAQ: BYND) once again landed in the spotlight as a new securities‑fraud investigation was announced — the latest in a growing stack of legal and financial headaches for the struggling plant‑based meat pioneer. GlobeNewswire At Friday’s close, Beyond Meat shares were trading around $0.86, down more than 75% year‑to‑date and sitting near…
McCormick (MKC) News Today — Nov 12, 2025: Big Funds Shift Stakes, BofA Adds MKC to ‘Beyond‑AI’ Stock Picks, Shares Edge Higher

McCormick (MKC) News Today — Nov 12, 2025: Big Funds Shift Stakes, BofA Adds MKC to ‘Beyond‑AI’ Stock Picks, Shares Edge Higher

What’s new on November 12, 2025 1) Institutions are repositioning around MKC Two notable fund disclosures hit the tape today: While 13F‑based stories reflect prior‑quarter positions, their publication today adds fresh context to how large holders are sizing MKC into year‑end. MarketBeat 2) BofA puts MKC on its “beyond AI” screen In a MarketWatch write‑up today, Bank of America urged…
Amaze Holdings (AMZE) Completes The Food Channel Acquisition; Plans Platform Revamp for Culinary Creators — Nov 12, 2025

Amaze Holdings (AMZE) Completes The Food Channel Acquisition; Plans Platform Revamp for Culinary Creators — Nov 12, 2025

NYSE American–listed Amaze Holdings closed its purchase of The Food Channel, paid via a convertible promissory note, and says a refreshed FoodChannel.com will soon serve its 60,000+ food creators. Shares were among early pre‑market movers. Amaze Holdings, Inc. What happened At 8:30 a.m. ET on November 12, 2025, Amaze Holdings, Inc. (NYSE American: AMZE) announced it completed the acquisition of…
Tyson Foods (TSN) beats Q4 estimates, lifts FY26 outlook as chicken strength offsets beef headwinds — stock up on Nov. 10, 2025

Tyson Foods (TSN) beats Q4 estimates, lifts FY26 outlook as chicken strength offsets beef headwinds — stock up on Nov. 10, 2025

What Tyson reported today (Q4 & FY2025) Tyson Foods posted fiscal Q4 2025 adjusted EPS of $1.15, topping consensus, on $13.86 billion in revenue. GAAP EPS was $0.13 as the quarter included $355 million in legal contingency accruals recognized as a reduction to sales. For the full fiscal year 2025, sales reached $54.44 billion (+2.1% YoY), adjusted operating income was…
Jack’s Donuts Bankruptcy Shakes Indiana – 64-Year-Old Doughnut Chain Faces Uncertain Future

Jack’s Donuts Bankruptcy Shakes Indiana – 64-Year-Old Doughnut Chain Faces Uncertain Future

Chapter 11 Filing and What It Means Jack’s Donuts – an Indiana-based donut chain founded in 1961 – stunned local fans and franchisees by filing for Chapter 11 bankruptcy protection in late October 2025 Whatnow. Chapter 11 is a form of bankruptcy that allows a business to reorganize its finances under court supervision rather than liquidate entirely Wrtv. In practical…
Beyond Meat (BYND) Stock Skyrockets 50% Amid Meme Mania – Turnaround or Dead Cat Bounce?

Beyond Meat’s Wild Ride: Stock Rockets 1300% Then Plunges 80% – Expert Analysis & Forecasts

BYND Stock Performance & Recent Volatility Beyond Meat’s share price has oscillated wildly in mid–late October 2025. In mid-October, after hitting all-time low ~$0.50 on Oct 16, the stock became the poster child of a new meme-stock squeeze. Over the week to Oct 22, BYND “rose nearly seven-fold,” according to Reuters Reuters. On Oct 20 the stock jumped +120%, then…
Kraft Heinz Stock Hits Lows Despite Q3 Earnings Beat – What’s Next for KHC?

Kraft Heinz Stock Hits Lows Despite Q3 Earnings Beat – What’s Next for KHC?

Q3 Earnings: Profit Beats, Sales Slip Slightly 📊 Kraft Heinz delivered a mixed third quarter, posting better-than-expected profits but a slight revenue miss. Net sales for Q3 2025 came in at $6.24 billion, down about 2.3% from a year ago, as the company faced soft consumer demand Gurufocus. Organic sales (which exclude currency and M&A effects) declined 2.5%, reflecting lower…
Krispy Kreme Stock Soars on Bold Global Expansion Amid U.S. Sales Slump

Krispy Kreme Stock Soars on Bold Global Expansion Amid U.S. Sales Slump

Krispy Kreme’s share price has bounced sharply this week, rekindling a meme-stock–style frenzy even as the doughnut chain struggles domestically. After closing at about $3.26 on Oct. 20, the stock jumped roughly 14% on Oct. 21 to around $3.7 Stockanalysis Marketbeat. Investors cited the recent news of Krispy Kreme’s aggressive overseas growth and renewed social-media hype, following a torrid year…
Beyond Meat Stock Implodes: 60% Crash After Shocking Debt-For-Equity Swap

Beyond Meat Stock Implodes: 60% Crash After Shocking Debt-For-Equity Swap

Debt Restructure Sparks Stock Crash Beyond Meat’s brand remains visible to consumers, but behind the scenes its finances are in crisis. In mid-October 2025 the company announced an early settlement of its convertible debt exchange offer, triggering a historic market reaction. As Reuters reports, BYND shareholders are “agonizing” after the company offered existing bondholders new debt and stock in place…
Nestlé Shares Soar 8% on Surprise Q3 Sales, 16,000-Job Cut Plan – What’s Next?

Nestlé Shocks Investors: 8% Stock Rally After Blowout Q3 and 16,000 Jobs on the Line

Key Facts: Nestlé’s stock jumped about 8% on Oct. 16 – its steepest one-day gain since 2008 Swissinfo ts2.tech. That followed a surprise 4.3% rise in Q3 organic sales (versus ~3.7% expected) Reuters, with its volume metric (real internal growth) at +1.5% (far above the +0.3% forecast) Reuters. New CEO Philipp Navratil announced a costly “turnaround” plan: 16,000 job cuts…

Stock Market Today

  • Agomab Therapeutics and SpyGlass Pharma Raise $350M in Nasdaq IPOs
    February 6, 2026, 4:52 AM EST. Belgian biotech Agomab Therapeutics and California-based SpyGlass Pharma went public on Nasdaq, raising a combined $350 million. Agomab priced 12.5 million shares at $16 each, aiming to generate $200 million for advancing immunology treatments including ontunisertib for Crohn's disease. SpyGlass priced 9.4 million shares at $16, targeting $150 million to fund long-acting eye drug delivery devices in phase 3 trials. Both companies gave underwriters options to buy additional shares, potentially boosting proceeds by $30 million for Agomab and $22.5 million for SpyGlass. Agomab focuses on ALK5 inhibitors, while SpyGlass develops drug-eluting intraocular lenses to reduce the need for eye drops. The IPOs highlight growing momentum in biopharma financing on Nasdaq.
Go toTop